Stock info Smith & Nephew | Filter  Basic-Info

Smith & Nephew

The headquarter of Smith & Nephew is based in London. Smith & Nephew primarily operates in the pharmaceutical sector. Between 2006 and 2016 the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The past year was a profitable year for the Smith & Nephew investors

Over the past year the company' stock gained around 4 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 104 percent. Smith & Nephew's revenues between 2011 and 2015 were quite stable and moved between 254,57 billion GBp and 314,43 billion GBp. Smith & Nephew's net results between 2011 and 2015 were very fluctuating and moved between 41,02 billion GBp and 55,77 billion GBp.

Smith & Nephew paid out dividends in the past 5 years. On average Smith & Nephew's dividend yield over the past 5 years was around 83,72 percent annually.

Smith & Nephew' balance mostly consists of equity

At the end of 2015 the English company had a balance sheet of 486,3 billion GBp. Last year the total debt of the company was 217,19 billion GBp. This equals around 44,66 percent of the total balance sheet. At the end of 2016 the English company was traded with a price/earnings-ratio of around 19. So investors paid 19 times the company's 2015's EPS. Many analysts say that based on her price/earnings-ratio and dividend yield the English stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 1079,95 billion GBp. At the end of 2015 the English company had around 894 million stocks listed on the exchanges.

All Smith & Nephew's annual reports can be found here. More information about Smith & Nephew can be found it's website. .